全球思覺失調症患者人數分析與預測：2026-2035年

全球思覺失調症數量仍然龐大，構成嚴重的公共衛生負擔，對有效的診斷、治療和長期疾病管理的需求持續存在。患者分析能夠全面揭示疾病的盛行率、發病率、已確診和已治療的患者人數、人口統計趨勢、疾病嚴重程度、性別分佈、特定年齡層盛行率、區域流行病學趨勢以及未來患者成長預測。隨著醫療保健系統內精神科服務的可及性不斷提高以及全球對精神健康的認知不斷增強，預計診斷率將有所提高，從而改善患者預後並擴大治療機會。

思覺失調症是一種慢性精神疾病，其特徵是感知、認知、情緒調節和行為的障礙。它通常始於青春期後期或成年早期，往往需要終身服藥、接受心理社會支持和持續的臨床監測。根據國際衛生組織統計，全球約有2,400萬人患有思覺失調症，但由於精神衛生保健服務不足、社會歧視以及精神衛生專業短缺，許多患者仍未被診斷或治療不足。未來幾年，透過進行宣傳活動、實施早期療育計畫以及擴大社區精神健康服務，有望提高患者的識別率。

患者數量受人口結構變化、都市化、社會經濟狀況、遺傳易感性、環境風險因素以及醫療保健服務可近性的影響。雖然思覺失調症在人群中的盛行率相對穩定，但存活率的提高、早期診斷以及治療機會的增加，導致接受長期照護的患者人數上升。精神病篩檢、數位心理健康平台、遠距精神病學以及人工智慧輔助診斷技術的進步，也有助於提高疾病檢出率和持續的病患監測。

對精神衛生保健基礎設施的投入增加、政府支持政策的強化、保險覆蓋範圍的擴大以及藥物創新技術的進步，持續加強全球思覺失調症治療生態系統。隨著綜合精神科護理和早期療育在醫療保健系統中日益普及，預計在預測期內，接受診斷和治療的患者人數將穩步成長。

區域洞察

由於北美擁有先進的醫療保健基礎設施、廣泛的心理健康意識、全面的保險覆蓋以及便捷的精神科醫生資源，該地區確診的思覺失調症患者數量位居世界前列。早期診斷工作和綜合行為健康計畫持續推動著患者識別和治療的改進。

在歐洲，相當數量的思覺失調症患者得到了完善的公共醫療體系、社區精神病護理和綜合精神健康政策的支持。德國、英國、法國、義大利和西班牙持續提供早期療育服務、復健計劃，並對精神病護理進行長期投入。

在亞太地區，由於醫療保健基礎設施的擴張、人們對心理健康的意識提升提高、精神病服務的增加以及中國、日本、印度、韓國和澳洲診斷途徑的改善，預計在預測期內，確診患者的數量將成長最快。

在拉丁美洲、中東和非洲，隨著醫療保健的現代化、精神病設施的擴建、意識提升以及政府主導的精神衛生政策的加強，思覺失調症的診斷和治療正在逐步改善。

本報告調查了全球思覺失調症患者數量的趨勢，總結了該疾病的概況和臨床背景、患者數量的趨勢和預測、按嚴重程度、臨床症狀、治療狀況和年齡層等各種類別進行的詳細分析、按地區和主要國家/地區分類的趨勢、競爭格局、主要公司概況以及未來展望。

目錄

第1章：執行摘要

第2章：調查方法

第3章：疾病概論及臨床背景

• 思覺失調症：概述
• 疾病的定義與分類
• 對疾病認知的歷史性變化
• 病理生理學
  • 功能障礙
  • 麩胺酸功能障礙
  • 神經發育因素
  • 遺傳貢獻
  • 環境風險因素
• 該疾病的症狀和臨床觀察
  • 陽性症狀
  • 陰性症狀
  • 認知症狀
  • 功能障礙
• 疾病嚴重程度分類
• 疾病進展模式
• 合併症
• 對死亡率和發病率的影響
• 對生活品質的影響

第4章：風險因子和發病機制的評估

• 遺傳風險因素
• 家族史和遺傳學
• 產前和周產期因素
• 環境決定因素
• 與藥物濫用相關的風險
• 都市化和社會經濟因素
• 與年齡相關的風險特徵
• 性別特異性風險模式

第5章：診斷狀態

• 診斷標準概述
  • 基於DSM的診斷
  • 基於ICD的診斷
• 對診斷過程的評估
• 分析診斷時間
• 早期檢測面臨的挑戰
• 誤診與漏診的趨勢
• 新的診斷方法
• 醫療保健服務可近性對診斷的影響

第6章 全球流行病學：概述

• 全球患者群體概況
• 患者總數
• 新患者總數
• 確診患者人數
• 接受治療的患者人數
• 未接受治療的患者人數
• 有症狀患者人數
• 按嚴重程度分類的患者人數
• 性別流行病學
• 年齡特異性流行病學
• 對死亡相關患者群體的分析
• 過去的流行病學趨勢
• 未來流行病學預測

第7章：患者細分分析

• 患者人數：依嚴重程度分類
  • 輕症患者
  • 中度患者
  • 重症疾病患者
• 患者人數：依臨床症狀
  • 以陽性症狀為主的患者
  • 以陰性症狀為主的患者
  • 以認知障礙為主要症狀的患者
  • 表現出混合症狀的患者
• 患者人數：依治療狀態
  • 已確診並正在接受治療
  • 已確診，但未治療
  • 未確診患者
• 病患人數：依醫療機構分類
  • 住院病人
  • 門診病人
  • 接受社區醫療保健和社區護理的患者
• 患者人數：依年齡層別分類
  • 兒童和青少年患者
  • 年輕成人患者
  • 成年患者
  • 老年患者
• 患者人數：依性別
  • 男性
  • 女士

第8章：疾病負擔評估

• 臨床負擔
• 對患者及其家庭帶來的負擔
• 經濟負擔
• 殘障負擔
• 社會負擔
• 醫療保健系統的負擔
• 生產力損失分析

第9章：獲得治療和醫療用途

• 治療趨勢概述
• 獲得精神科護理的機會
• 獲得抗精神病藥物治療
• 長效注射劑（LAI）的使用趨勢
• 依從性與治療連續性分析
• 住院趨勢
• 復發和再入院模式
• 治療差距評估
• 疾病管理中未被滿足的需求

第10章 區域分析

• 北美洲
• 歐洲
• 亞太地區
• 拉丁美洲

第11章 主要國家分析

• 加拿大
• 德國
• 中國
• 日本
• 印度

第12章：預測分析

• 全球患者數量預測
• 預計確診患者人數
• 預測需要治療的患者人數
• 預測未治療患者人數
• 按年齡層預測的趨勢
• 性別預測趨勢
• 區域成長機遇
• 各國具體成長預測
• 基於情境的預測建模

第13章：新趨勢與未來展望

• 診斷方法的演變
• 早期療育的趨勢
• 數字精神醫學的整合
• 人工智慧驅動的心理健康篩檢
• 精準精神醫學的發展
• 生物標記研究的影響
• 預測未來疾病負擔
• 對相關利益者的策略意義

第14章附錄

The global schizophrenia patient population continues to represent a significant public health burden, creating sustained demand for effective diagnosis, treatment, and long-term disease management. Patient population analysis provides comprehensive insights into disease prevalence, incidence, diagnosed and treated patient populations, demographic trends, disease severity, gender distribution, age-specific prevalence, regional epidemiology, and future patient growth projections. As healthcare systems continue improving access to psychiatric services and mental health awareness increases worldwide, diagnosis rates are expected to improve, supporting better patient outcomes and expanding treatment opportunities.

Schizophrenia is a chronic psychiatric disorder characterized by disturbances in perception, cognition, emotional regulation, and behavior. The disorder typically develops during late adolescence or early adulthood and often requires lifelong medical treatment, psychosocial support, and continuous clinical monitoring. According to international health organizations, schizophrenia affects approximately 24 million people worldwide, with many additional cases remaining undiagnosed or inadequately treated due to limited access to mental healthcare, social stigma, and shortages of mental health professionals. Increasing public awareness campaigns, early intervention initiatives, and expanded community mental health services are expected to improve case identification over the coming years.

The patient population is influenced by demographic changes, urbanization, socioeconomic conditions, genetic susceptibility, environmental risk factors, and healthcare accessibility. Although schizophrenia prevalence remains relatively stable across populations, improvements in survival rates, earlier diagnosis, and expanded treatment access are increasing the number of patients receiving long-term care. Advances in psychiatric screening, digital mental health platforms, telepsychiatry, and artificial intelligence-assisted diagnostic support are also contributing to improved disease detection and ongoing patient monitoring.

Growing investments in mental healthcare infrastructure, supportive government policies, expanding insurance coverage, and increasing pharmaceutical innovation continue strengthening the global schizophrenia treatment ecosystem. As healthcare systems place greater emphasis on integrated psychiatric care and early intervention, the diagnosed and treated patient population is expected to increase steadily throughout the forecast period.

Market Drivers

Increasing Mental Health Awareness

Rising public awareness regarding psychiatric disorders is encouraging earlier diagnosis and improved access to professional mental healthcare services.

Educational campaigns and anti-stigma initiatives are contributing to increased treatment-seeking behavior.

Expansion of Early Diagnosis Programs

Healthcare systems are increasingly emphasizing early intervention and specialized psychiatric assessment.

Earlier diagnosis improves long-term disease management while expanding the diagnosed patient population.

Growth of Community Mental Healthcare

Governments continue investing in community-based psychiatric services, rehabilitation programs, and integrated behavioral healthcare.

These initiatives improve patient access to long-term treatment and support services.

Advances in Diagnostic Technologies

Digital mental health platforms, telepsychiatry, electronic health records, and artificial intelligence-assisted clinical decision support are improving diagnostic accuracy and patient monitoring.

Technology is enhancing continuity of care across healthcare settings.

Increasing Healthcare Investment

Growing investment in psychiatric hospitals, specialist mental health centers, and healthcare infrastructure continues strengthening schizophrenia diagnosis and treatment worldwide.

Market Restraints

Underdiagnosis and Delayed Treatment

Many individuals with schizophrenia remain undiagnosed because of limited mental healthcare access, social stigma, and inadequate psychiatric resources.

Delayed diagnosis often results in poorer long-term clinical outcomes.

Social Stigma

Persistent stigma associated with mental illness discourages many individuals from seeking professional medical care.

Social discrimination continues affecting treatment adherence and disease management.

Limited Specialist Availability

Many low- and middle-income countries continue experiencing shortages of psychiatrists, psychologists, and specialized mental healthcare professionals.

Workforce limitations may restrict timely diagnosis and long-term patient management.

Patient Population Insights

By Disease Stage

The diagnosed patient population includes individuals experiencing first-episode psychosis, chronic schizophrenia, treatment-resistant schizophrenia, and patients receiving long-term maintenance therapy.

Growing emphasis on early intervention is increasing diagnosis during the initial stages of disease progression.

By Age Group

Schizophrenia most commonly develops during late adolescence and early adulthood, with the majority of diagnoses occurring between 15 and 35 years of age.

Older adults living with chronic schizophrenia continue representing an important segment requiring long-term psychiatric care and supportive services.

By Gender

Schizophrenia affects both males and females, although males generally experience earlier disease onset and may develop more severe clinical symptoms during early adulthood.

Female patients often experience later onset and may demonstrate different disease progression patterns.

By Treatment Status

The patient population includes diagnosed individuals receiving pharmacological therapy, psychosocial interventions, rehabilitation services, community mental healthcare, and long-term follow-up, as well as untreated or inadequately treated patients requiring improved healthcare access.

Regional Insights

North America represents one of the largest diagnosed schizophrenia patient populations owing to advanced healthcare infrastructure, widespread mental health awareness, comprehensive insurance coverage, and strong access to psychiatric specialists. Early diagnosis initiatives and integrated behavioral healthcare programs continue supporting improved patient identification and treatment.

Europe maintains a substantial schizophrenia patient population supported by well-established public healthcare systems, community-based psychiatric care, and comprehensive mental health policies. Germany, the United Kingdom, France, Italy, and Spain continue investing in early intervention services, rehabilitation programs, and long-term psychiatric care.

Asia Pacific is expected to witness the fastest growth in diagnosed patient numbers during the forecast period due to expanding healthcare infrastructure, improving mental health awareness, increasing psychiatric services, and greater access to diagnosis across China, Japan, India, South Korea, and Australia.

Latin America and the Middle East & Africa are gradually improving schizophrenia diagnosis and treatment through healthcare modernization, expanding psychiatric care facilities, increasing public awareness, and strengthening government-supported mental health initiatives.

Competitive and Strategic Outlook

The growing diagnosed schizophrenia patient population continues creating significant opportunities for pharmaceutical companies, healthcare providers, diagnostic technology developers, digital health companies, and mental healthcare service organizations. Market participants are increasingly focusing on improving early diagnosis, expanding patient access, supporting long-term treatment adherence, and integrating digital mental health solutions into routine clinical practice.

Strategic investments continue targeting telepsychiatry platforms, artificial intelligence-assisted diagnostic technologies, remote patient monitoring, digital therapeutics, community mental healthcare, and personalized psychiatric medicine. Partnerships between healthcare providers, research institutions, governments, and pharmaceutical companies are strengthening mental healthcare delivery while supporting improved patient outcomes.

Future market development is expected to emphasize early detection, precision psychiatry, integrated behavioral healthcare, digital patient engagement, and expanded access to comprehensive psychiatric services across both developed and emerging healthcare markets.

Conclusion

The global schizophrenia patient population is expected to increase steadily throughout the forecast period as mental health awareness improves, healthcare infrastructure expands, and access to psychiatric services continues strengthening worldwide. Advances in diagnostic technologies, community-based care, digital health solutions, and early intervention programs are expected to improve diagnosis rates and long-term disease management. Although challenges related to social stigma, underdiagnosis, specialist shortages, and unequal healthcare access remain, continued investment in mental healthcare systems and psychiatric innovation is expected to enhance patient outcomes while supporting sustainable growth across the schizophrenia treatment landscape.

Key Benefits of this Report

• Insightful Analysis: Comprehensive evaluation of global schizophrenia prevalence, incidence, diagnosed patient population, treatment patterns, and demographic trends.
• Patient Population Assessment: Analyze disease burden, age and gender distribution, disease stages, and treatment coverage across major regions.
• Market Drivers and Future Trends: Understand epidemiological developments, healthcare access improvements, and future patient population growth.
• Actionable Recommendations: Support market forecasting, clinical development planning, healthcare resource allocation, and commercial strategy.
• Caters to a Wide Audience: Suitable for pharmaceutical companies, biotechnology firms, healthcare providers, investors, consultants, research organizations, public health agencies, and policymakers.

What Businesses Use Our Reports For

Patient population forecasting, epidemiology assessment, commercial opportunity evaluation, healthcare planning, clinical trial strategy, market entry analysis, product launch planning, investment decision-making, and competitive intelligence.

Report Coverage

• Historical analysis from 2021 to 2024, Base year 2025, and Forecast period from 2026 to 2035
• Patient population analysis by prevalence, incidence, diagnosed cases, treated population, disease stage, age group, gender, and region
• Epidemiological trends, healthcare access, diagnosis patterns, and future patient growth projections
• Assessment of disease burden, treatment coverage, unmet clinical needs, and healthcare infrastructure
• Regional analysis across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Key Findings
• 1.2 Epidemiology Snapshot
• 1.3 Global Disease Burden Overview
• 1.4 Diagnosed and Treated Population Overview
• 1.5 Major Epidemiological Trends
• 1.6 Regional Patient Distribution Summary
• 1.7 Forecast Highlights
• 1.8 Strategic Insights for Stakeholders

2. Study Scope and Methodology

• 2.1 Report Objectives
• 2.2 Study Assumptions and Limitations
• 2.3 Epidemiological Framework
  • 2.3.1 Population-Based Modeling Approach
  • 2.3.2 Incidence-Based Modeling Approach
  • 2.3.3 Prevalence-Based Modeling Approach
• 2.4 Data Collection Methodology
  • 2.4.1 Primary Sources
  • 2.4.2 Secondary Sources
  • 2.4.3 Registry-Based Evidence
  • 2.4.4 Peer-Reviewed Literature Assessment
• 2.5 Forecasting Methodology
  • 2.5.1 Historical Trend Analysis
  • 2.5.2 Epidemiological Projection Models
  • 2.5.3 Scenario Analysis Framework
• 2.6 Data Validation and Quality Assurance

3. Disease Overview and Clinical Background

• 3.1 Introduction to Schizophrenia
• 3.2 Disease Definition and Classification
• 3.3 Historical Evolution of Disease Understanding
• 3.4 Pathophysiology
  • 3.4.1 Dopaminergic Dysfunction
  • 3.4.2 Glutamatergic Dysfunction
  • 3.4.3 Neurodevelopmental Factors
  • 3.4.4 Genetic Contributions
  • 3.4.5 Environmental Risk Factors
• 3.5 Disease Symptoms and Clinical Manifestations
  • 3.5.1 Positive Symptoms
  • 3.5.2 Negative Symptoms
  • 3.5.3 Cognitive Symptoms
  • 3.5.4 Functional Impairment
• 3.6 Disease Severity Classification
• 3.7 Disease Progression Patterns
• 3.8 Comorbid Conditions
• 3.9 Mortality and Morbidity Impact
• 3.10 Quality of Life Burden

4. Risk Factor and Etiology Assessment

• 4.1 Genetic Risk Factors
• 4.2 Family History and Heritability
• 4.3 Prenatal and Perinatal Factors
• 4.4 Environmental Determinants
• 4.5 Substance Abuse-Related Risk
• 4.6 Urbanization and Socioeconomic Factors
• 4.7 Age-Associated Risk Profiles
• 4.8 Gender-Specific Risk Patterns

5. Diagnostic Landscape

• 5.1 Diagnostic Criteria Overview
  • 5.1.1 DSM-Based Diagnosis
  • 5.1.2 ICD-Based Diagnosis
• 5.2 Diagnostic Journey Assessment
• 5.3 Time to Diagnosis Analysis
• 5.4 Challenges in Early Detection
• 5.5 Misdiagnosis and Underdiagnosis Trends
• 5.6 Emerging Diagnostic Approaches
• 5.7 Healthcare Access Impact on Diagnosis

6. Global Epidemiology Overview

• 6.1 Global Population Overview
• 6.2 Total Prevalent Cases
• 6.3 Total Incident Cases
• 6.4 Diagnosed Prevalent Cases
• 6.5 Treated Patient Population
• 6.6 Untreated Patient Population
• 6.7 Symptomatic Patient Population
• 6.8 Severity-Specific Patient Population
• 6.9 Gender-Specific Epidemiology
• 6.10 Age-Specific Epidemiology
• 6.11 Mortality-Associated Population Analysis
• 6.12 Historical Epidemiological Trends
• 6.13 Forecasted Epidemiological Trends

7. Patient Segmentation Analysis

• 7.1 Patient Population by Disease Severity
  • 7.1.1 Mild Disease Population
  • 7.1.2 Moderate Disease Population
  • 7.1.3 Severe Disease Population
• 7.2 Patient Population by Clinical Presentation
  • 7.2.1 Predominantly Positive Symptoms
  • 7.2.2 Predominantly Negative Symptoms
  • 7.2.3 Cognitive Impairment Dominant Cases
  • 7.2.4 Mixed Symptom Presentation
• 7.3 Patient Population by Treatment Status
  • 7.3.1 Diagnosed and Treated
  • 7.3.2 Diagnosed but Untreated
  • 7.3.3 Undiagnosed Cases
• 7.4 Patient Population by Healthcare Setting
  • 7.4.1 Inpatient Population
  • 7.4.2 Outpatient Population
  • 7.4.3 Community-Based Population
• 7.5 Patient Population by Age Group
  • 7.5.1 Pediatric and Adolescent Population
  • 7.5.2 Young Adult Population
  • 7.5.3 Adult Population
  • 7.5.4 Elderly Population
• 7.6 Patient Population by Gender
  • 7.6.1 Male Population
  • 7.6.2 Female Population

8. Disease Burden Assessment

• 8.1 Clinical Burden
• 8.2 Humanistic Burden
• 8.3 Economic Burden
  • 8.3.1 Direct Healthcare Costs
  • 8.3.2 Indirect Costs
  • 8.3.3 Caregiver Burden
• 8.4 Disability Burden
• 8.5 Social Burden
• 8.6 Healthcare System Burden
• 8.7 Productivity Loss Analysis

9. Treatment Access and Healthcare Utilization

• 9.1 Treatment Landscape Overview
• 9.2 Access to Psychiatric Care
• 9.3 Access to Antipsychotic Therapy
• 9.4 Long-Acting Injectable Utilization Trends
• 9.5 Adherence and Persistence Analysis
• 9.6 Hospitalization Trends
• 9.7 Relapse and Readmission Patterns
• 9.8 Treatment Gap Assessment
• 9.9 Unmet Needs in Disease Management

10. Geographic Analysis (Regional Level Only)

• 10.1 North America
  • 10.1.1 Total Patient Population
  • 10.1.2 Diagnosed Population
  • 10.1.3 Treated Population
  • 10.1.4 Epidemiological Trends
  • 10.1.5 Healthcare Access Assessment
• 10.2 Europe
  • 10.2.1 Total Patient Population
  • 10.2.2 Diagnosed Population
  • 10.2.3 Treated Population
  • 10.2.4 Epidemiological Trends
  • 10.2.5 Healthcare Access Assessment
• 10.3 Asia-Pacific
  • 10.3.1 Total Patient Population
  • 10.3.2 Diagnosed Population
  • 10.3.3 Treated Population
  • 10.3.4 Epidemiological Trends
  • 10.3.5 Healthcare Access Assessment
• 10.4 Latin America
  • 10.4.1 Total Patient Population
  • 10.4.2 Diagnosed Population
  • 10.4.3 Treated Population
  • 10.4.4 Epidemiological Trends
  • 10.4.5 Healthcare Access Assessment
• 10.5 Middle East & Africa
  • 10.5.1 Total Patient Population
  • 10.5.2 Diagnosed Population
  • 10.5.3 Treated Population
  • 10.5.4 Epidemiological Trends
  • 10.5.5 Healthcare Access Assessment

11. Key Countries Analysis

• 11.1 United States
  • 11.1.1 Total Prevalent Population
  • 11.1.2 Diagnosed Population
  • 11.1.3 Treated Population
  • 11.1.4 Epidemiological Forecast
• 11.2 Canada
  • 11.2.1 Total Prevalent Population
  • 11.2.2 Diagnosed Population
  • 11.2.3 Treated Population
  • 11.2.4 Epidemiological Forecast
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 China
• 11.9 Japan
• 11.10 India
• 11.11 South Korea
• 11.12 Australia
• 11.13 Brazil
• 11.14 Mexico
• 11.15 Saudi Arabia
• 11.16 South Africa

12. Forecast Analysis (2025-2035)

• 12.1 Global Patient Population Forecast
• 12.2 Diagnosed Population Forecast
• 12.3 Treated Population Forecast
• 12.4 Untreated Population Forecast
• 12.5 Age-Specific Forecast Trends
• 12.6 Gender-Specific Forecast Trends
• 12.7 Regional Growth Opportunities
• 12.8 Country-Level Growth Outlook
• 12.9 Scenario-Based Forecast Modeling

13. Emerging Trends and Future Outlook

• 13.1 Evolution of Diagnostic Practices
• 13.2 Early Intervention Trends
• 13.3 Digital Psychiatry Integration
• 13.4 AI-Enabled Mental Health Screening
• 13.5 Precision Psychiatry Developments
• 13.6 Biomarker Research Impact
• 13.7 Future Disease Burden Projections
• 13.8 Strategic Implications for Stakeholders

14. Appendix

• 14.1 Abbreviations
• 14.2 Epidemiology Definitions
• 14.3 Data Sources
• 14.4 Statistical Models Used
• 14.5 Country Grouping Methodology
• 14.6 Glossary of Terms